secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001437749-24-025200
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica updates on ReMEDy2 trial, starts preeclampsia study, extends cash to Q3 2026
--------------------------------------------------------------------------------

- ReMEDy2 AIS interim analysis enrollment (n=144) targeted for Q1 2025; 15 top U.S. centers prioritized.
- Phase 2 preeclampsia trial begins Q4 2024; proof-of-concept results expected H1 2025.
- Completed $11.8M private placement ($2.50/share, ~10% premium) in June 2024; net proceeds $11.7M.
- Cash, cash equivalents and investments $54.1M as of June 30, 2024; working capital $51.9M.
- R&D expenses $3.9M for Q2 2024 (up from $2.5M Q2 2023); net cash used in operations $11.2M H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924025200/0001437749-24-025200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924025200/dmtp20240807_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer